Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development | BMC Cancer | Full Text

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development | BMC Cancer | Full Text

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration ...

Authors:Jennifer S. Davis, Preeti Kanikarla-Marie, Mihai Gagea, Patrick L. Yu, Dexing Fang, Manu Sebastian, Peiying Yang, Ernest Hawk, Roderick Dashwood, Lenard M. Lichtenberger, David Menter and Scott Kopetz

Citation:BMC Cancer 2020 20:871

Content type:Research article

 

Published on: 10 September 2020

• ViewFull Text
 
• ViewPDF